The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome

Carcinogenesis

Volumn 35, Issue 3, 2014, Pages 586-596

  Avery Kiejda, Kelly A ^a,b   Morten, Brianna ^a,b   Wong Brown, Michelle W ^a,b   Mathe, Andrea ^a,b   Scott, Rodney J ^a,b,c  

^a HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c JOHN HUNTER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER SIZE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PROTEIN ISOFORMS; RNA, MESSENGER; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84895828901     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt411     Document Type: Article

References (51)

1. Rozan,L.M. et al. (2007) p53 downstream target genes and tumor suppression: a classical view in evolution. Cell Death Differ., 14, 3-9.
2. Vogelstein,B. et al. (2000) Surfing the p53 network. Nature, 408, 307-310.
3. Miller,L.D. et al. (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl Acad. Sci. USA, 102, 13550-13555.
4. Olivier,M. et al. (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol., 2, a001008.
5. Vousden,K.H. et al. (2002) Live or let die: the cell's response to p53. Nat. Rev. Cancer, 2, 594-604.
6. Chang,C.J. et al. (2011) p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat. Cell Biol., 13, 317-323.
7. Wang,S.P. et al. (2009) p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat. Cell Biol., 11, 694-704.
8. D'Assoro,A.B. et al. (2008) Impaired p53 function leads to centrosome amplification, acquired ERalpha phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts. Oncogene, 27, 3901-3911.
9. Sablina,A.A. et al. (2003) Tumor suppressor p53 and its homologue p73alpha affect cell migration. J. Biol. Chem., 278, 27362-27371.
10. Xia,M. et al. (2007) Tumor suppressor p53 restricts Ras stimulation of RhoA and cancer cell motility. Nat. Struct. Mol. Biol., 14, 215-223.
11. Mehta,S.A. et al. (2007) Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion. Oncogene, 26, 3329-3337.
12. Kamangar,F. et al. (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol., 24, 2137-2150.
13. Schmidt,M.K. et al. (2007) Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res., 67, 9584-9590.
14. Coutant,C. et al. (2011) Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. Clin. Cancer Res., 17, 2591-2601.
15. Oshima,K. et al. (2011) Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/epirubicin/ cyclophosphamide in human breast cancer. Cancer Lett., 307, 149-157.
16. Bourdon,J.C. et al. (2005) p53 isoforms can regulate p53 transcriptional activity. Genes Dev., 19, 2122-2137.
17. Marcel,V. et al. (2010) ?160p53 is a novel N-terminal p53 isoform encoded by ?133p53 transcript. FEBS Lett., 584, 4463-4468.
18. Ghosh,A. et al. (2004) Regulation of human p53 activity and cell localization by alternative splicing. Mol. Cell. Biol., 24, 7987-7997.
19. Yin,Y. et al. (2002) p53 Stability and activity is regulated by Mdm2- mediated induction of alternative p53 translation products. Nat. Cell Biol., 4, 462-467.
20. Powell,D.J. et al. (2008) Stress-dependent changes in the properties of p53 complexes by the alternative translation product p53/47. Cell Cycle, 7, 950-959.
21. Anensen,N. et al. (2006) A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clin. Cancer Res., 12, 3985-3992.
22. Fujita,K. et al. (2009) p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat. Cell Biol., 11, 1135-1142.
23. Hofstetter,G. et al. (2010) Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. Oncogene, 29, 1997-2004.
24. Song,W. et al. (2009) Expression of p53 isoforms in renal cell carcinoma. Chin. Med. J. (Engl)., 122, 921-926.
25. Avery-Kiejda,K.A. et al. (2008) Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNAdamaging agent cisplatin. Clin. Cancer Res., 14, 1659-1668.
26. Bourdon,J.C. et al. (2011) p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res., 13, R7.
27. Moore,H.C. et al. (2010) The RNA helicase p68 modulates expression and function of the δ133 isoform(s) of p53, and is inversely associated with δ133p53 expression in breast cancer. Oncogene, 29, 6475-6484.
28. Hofstetter,G. et al. (2012) The N-terminally truncated p53 isoform δ40p53 influences prognosis in mucinous ovarian cancer. Int. J. Gynecol. Cancer, 22, 372-379.
29. Avery-Kiejda,K.A. et al. (2011) P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer, 11, 203.
30. Wong,M.W. et al. (2011) BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. Breast Cancer Res. Treat., 127, 853-859.
31. Kumar,P. et al. (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc., 4, 1073-1081.
32. Ng,P.C. et al. (2003) SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res., 31, 3812-3814.
33. Courtois,S. et al. (2002) DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene, 21, 6722-6728.
34. Hasfi,H.et al. (2013) Effects of δ40p53, an isoform of p53 lacking the N-terminus, on transactivation capacity of the tumor suppressor protein p53. BMC Cancer, 13, 134.
35. Olivier,M. et al. (2006) The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin. Cancer Res., 12, 1157-1167.
36. Petitjean,A. et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat., 28, 622-629.
37. Yu,J. et al. (2005) The transcriptional targets of p53 in apoptosis control. Biochem. Biophys. Res. Commun., 331, 851-858.
38. Bourougaa,K. et al. (2010) Endoplasmic reticulum stress induces G2 cellcycle arrest via mRNA translation of the p53 isoform p53/47. Mol. Cell, 38, 78-88.
39. Podo,F.et al. (2010) Triple-negative breast cancer: present challenges and new perspectives. Mol. Oncol, 4, 209-229.
40. Carey,L. et al. (2010) Triple-negative breast cancer: disease entity or title of convenience? Nat. Rev. Clin. Oncol., 7, 683-692.
41. Lin,S.C. et al. (2013) The human δNp53 isoform triggers metabolic and gene expression changes that activate mTOR and alter mitochondrial function. Aging Cell, 12, 863-872.
42. Takahashi,R., et al. (2013) Dominant effects of δ40p53 on p53 function and melanoma cell fate. J Invest Dermatol. doi:10.1038/jid.2013.391.[Epub ahead of print]
43. Ungewitter,E. et al. (2010) Delta40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs. Genes Dev., 24, 2408-2419.
44. Maier,B. et al. (2004) Modulation of mammalian life span by the short isoform of p53. Genes Dev., 18, 306-319.
45. Davidson,W.R. et al. (2010) Differential regulation of p53 function by the N-terminal δNp53 and δ113p53 isoforms in zebrafish embryos. BMC Dev. Biol., 10, 102.
46. Boldrup,L. et al. (2007) Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur. J. Cancer, 43, 617-623.
47. Bernard,H. et al. (2013) The p53 isoform, δ133p53a, stimulates angiogenesis and tumour progression. Oncogene, 32, 2150-2160.
48. Silden,E. et al. (2013) Expression of TP53 isoforms p53β or p53γ enhances chemosensitivity in TP53(null) cell lines. PLoS One, 8, e56276.
49. Slatter,T.L. et al. (2011) Hyperproliferation, cancer, and inflammation in mice expressing a δ133p53-like isoform. Blood, 117, 5166-5177.
50. Zoric,A. et al. (2013) Differential effects of diverse p53 isoforms on TAp73 transcriptional activity and apoptosis. Carcinogenesis, 34, 522-529.
51. Marcel,V. et al. (2011) G-quadruplex structures in TP53 intron 3: role in alternative splicing and in production of p53 mRNA isoforms. Carcinogenesis, 32, 271-278.